ACOG

Alpha Cognition Inc. Common Stock (ACOG)

Stock · NASDAQ

$9.2as of 8/28/2026

Active signals

High Beta100.0%
Support level
$5.78

About ACOG

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-se…

Employees
71

Fundamentals

1-day range
$8.6$9.21
Market cap
$188.78M
P/E (trailing)
P/E (forward)
-14.49
EPS (trailing)
$-1.34
Dividend yield
Beta
8.65
Avg. volume
63.4K
52-week range
$4.5$10.14
Next earnings: August 13, 2026 · EPS estimate $-0.39

Forecasts

4 analyst ratings

Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$20
+117.4%
Median
$16
+73.9%
Low
$12
+30.4%

Latest news

Insider Activity

Insider Actions
Acquired
384.2K
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
10.51M
Total value held
$57.71M
Institutional holders
24
Top holders this quarter
  • Unknown2.56M
  • Unknown1.92M
  • Unknown1.67M
  • Unknown1.38M
  • Unknown1.06M
  • Unknown567.6K
  • Unknown365.0K
  • Unknown256.4K
  • Unknown218.5K
  • Unknown188.6K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.